Honest, research-backed journalism on ivermectin, fenbendazole, HCQ, and your right to medical sovereignty. Updated daily.
A short azithromycin course works because the drug builds up inside cells and tissues and leaves slowly. Here is what the research shows, and what it means for patients.
A 2012 Vanderbilt study linked azithromycin to a small rise in cardiovascular death, prompting an FDA warning. Here is what it found, who is at risk, and what later research added.
A pyloric stenosis signal tied to erythromycin in newborns quietly reshaped how doctors treat whooping cough in infants, favoring azithromycin instead.
A single oral dose of azithromycin, paired with surgery, hygiene, and sanitation, has become the backbone of the global effort to end trachoma blindness.
A close look at who genuinely benefits from post-exposure azithromycin after a whooping cough exposure, the 21-day window that matters, and what CDC guidance actually says.
A single oral dose of azithromycin is replacing painful penicillin shots in the global campaign against yaws. Here is what the evidence actually shows.
Azithromycin was long the go-to single-dose chlamydia treatment, but new evidence has shifted guidance toward doxycycline. Here's what changed, why, and what remains true.
Azithromycin's short course isn't a shortcut — it reflects unique pharmacokinetics that let the drug keep working long after the last pill.
Long-term, low-dose azithromycin reduces flare-ups in COPD and bronchiectasis in well-conducted trials—but the benefit carries real trade-offs worth understanding.